Tema Oncology ETF

CANC

Market cap $106M

NEW YORK--(BUSINESS WIRE)--Tema ETFs (“Tema”), the New York-based manager of innovative exchange-traded funds (ETFs), is pleased to announce the Tema Oncology ETF (“CANC”) has surpassed $100m in assets under management (AUM) two years since launch. The CANC ETF invests in leading oncology companies and cancer therapies and is the only pure-play oncology focused ETF in the world, managed by Dr. David Song MD, PhD, CFA.1 Key Highlights of the Tema Oncology ETF (CANC): 1. Rising Oncology Need Canc.

Be thankful for this year's resilient ETFs -- BWET, LITP, PINK and CANC -- which shined despite volatility, tariffs, AI worries and Fed shifts.

NEW YORK--(BUSINESS WIRE)--Tema ETFs (“Tema”), the New York-based provider of innovative exchange traded funds (ETFs), has surpassed $1 billion in assets under management (AUM) in just two years since launch, achieved with less than $5m of initial seed AUM. Tema also announces the hiring of Devan O'Dowd as Head of Distribution and Ceri Llewelyn as Director of Marketing. Three highlights to note: Institutional Adoption: Tema estimates that over 90% of current AUM originates from Registered Inves.

Medical breakthroughs are occurring constantly, but they often get lost in the news headlines unless they directly impact our lives. I wanted to take a moment to highlight a few recent medical breakthroughs and developments and explore a few ways to get actionable exposure to them with ETFs.